The estimated Net Worth of Brian Lee Baker is at least $6.29 millió dollars as of 22 March 2021. Mr. Baker owns over 28,435 units of Turning Point Therapeutics Inc stock worth over $2,474,202 and over the last 6 years he sold TPTX stock worth over $3,819,158. In addition, he makes $0 as Vice President - Finance and Administration at Turning Point Therapeutics Inc.
Sign up
Mr. Baker TPTX stock SEC Form 4 insiders trading
Brian has made over 3 trades of the Turning Point Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 28,435 units of TPTX stock worth $132,791 on 22 March 2021.
The largest trade he's ever made was selling 31,238 units of Turning Point Therapeutics Inc stock on 7 January 2021 worth over $3,819,158. On average, Brian trades about 12,495 units every 140 days since 2019. As of 22 March 2021 he still owns at least 32,551 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Mr. Baker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Baker biography
Brian L. Baker CPA serves as Vice President - Finance and Administration of the Company. Previously, Mr. Baker served as the Vice President, Finance at Cleave Biosciences, Inc. from February 2013 until July 2017. From 2011 through 2013, Mr. Baker worked as an independent finance consultant to multiple companies in the life science industry. From 2006 through 2010, Mr. Baker held positions of increasing responsibility, including Vice President Finance and Principal Accounting Officer, with Phenomix Corporation. From 2000 through 2006, Mr. Baker held positions of increasing responsibility with Cengent Therapeutics, Inc., (previously Structural Bioinformatics, Inc.). Mr. Baker began his accounting career with Pricewaterhouse Coopers (previously Price Waterhouse) from 1996 through 2000. Mr. Baker received a B.S. in Business Administration—Accounting and an M.S. in Business Administration—Information Systems from San Diego State University. Mr. Baker maintains an active certified public accounting license in the state of California.
How old is Brian Baker?
Brian Baker is 53, he's been the Vice President - Finance and Administration of Turning Point Therapeutics Inc since 2017. There are 8 older and 10 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
What's Brian Baker's mailing address?
Brian's mailing address filed with the SEC is C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, STE. 200, SAN DIEGO, CA, 92121.
Insiders trading at Turning Point Therapeutics Inc
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado és Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
What does Turning Point Therapeutics Inc do?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
What does Turning Point Therapeutics Inc's logo look like?
Complete history of Mr. Baker stock trades at Turning Point Therapeutics Inc
Turning Point Therapeutics Inc executives and stock owners
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Yi Larson,
Chief Financial Officer, Executive Vice President -
Mohammad Hirmand,
Executive Vice President, Chief Medical Officer -
Annette North,
Executive Vice President, General Counsel, Secretary -
Dr. Athena Maria Countouriotis M.D.,
Pres, CEO & Director -
Andrew John Partridge,
Exec. VP & Chief Commercial Officer -
Carol Gallagher,
Independent Director -
Dr. Mohammad Hirmand,
Exec. VP & Chief Medical Officer -
Patrick Machado,
Independent Director -
Annette C. North Esq., LLB,
Exec. VP, Gen. Counsel & Company Sec. -
Dr. Siegfried Reich Ph.D.,
Exec. VP & Chief Scientific Officer -
Simeon George,
Independent Director -
Sheila Gujrathi,
Chairman of the Board -
Jacob Chacko,
Independent Director -
Jim Mazzola,
IR Contact Officer -
Garry Nicholson,
Independent Director -
Heather Adams,
Vice President of Human Resources -
Brian Baker,
Vice President - Finance and Administration -
Siegfried Reich,
Executive Vice President, Chief Scientific Officer -
Athena Countouriotis,
President, Chief Executive Officer, Director -
Dr. Jeffrey P. Whitten,
Sr. VP of Pre-Clinical Devel. -
Brian Sun J.D., M.S.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Gavin Hirst Ph.D.,
Sr. VP of Chemistry & Interim Chief Scientific Officer -
Raymond J. Furey J.D.,
Sr. VP & Chief Compliance Officer -
Dr. Adam D. Levy M.B.A., Ph.D.,
Sr. VP of Investor Relations & Corp. Communications -
Ed Gemo,
Sr. VP & Chief Information Officer -
Kyri K. Van Hoose,
VP of Accounting & Interim Principal Accounting Officer -
Paolo Tombesi,
Exec. VP & CFO -
Jingrong Jean Cui,
Director -
Plc Gsk,
Director -
Hongbo Lu,
Director -
Advisors Llc Orbi Med Capit...,
-
Asset Management, Lp Chen B...,
-
Carl L Gordon,
Director -
Barbara W. Bodem,
Director -
Mark J Alles,
Director -
Paolo Tombesi,
EVP & Chief Financial Officer -
Brian Sun,
SVP & General Counsel -
Steve M Sabus,
SVP & Chief Commercial Officer